Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Bracelet-1 90 day exclusivity should be over x Feb 2023

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 23, 2022 12:34pm

218 Views

Post# 35122377

RE:The Bracelet-1 90 day exclusivity should be over x Feb 2023

PrECOG, LLC. announced the enrollment of the final patient in the Bracelet-1 study on June 24, 2022 - when adding in the pre-set 16 weeks for the data assessment takes the timeline to October 14, 2022 - then add in a very generous 4 weeks to write the report to be delivered to Merck KGaA/Pfizer - brings the timeline to November 4, 2022.

The 90 days exclusivity period started on November 04, 2022 - taking Merck KGaA/Pfizer's 90 day period of exclusivity to February 03, 2023.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023